Operating Segments (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Segment reporting
Total revenues	$ 166,140	$ 186,198	$ 582,843	$ 548,615
Loss from operations	(3,081,244)	(3,364,911)	(10,668,926)	(8,587,177)
Amortization and depreciation	4,793	8,875	21,538	26,614
Other (Expense) Income, Net	(227,759)	(222,640)	(530,793)	(124,662)
Share-based compensation	70,715	79,721	220,656	255,147
Identifiable Assets	17,947,373		$ 17,947,373		$ 26,869,927
Number of operating segments | segment			2
Operating Segments [Member] | Specialized BioTherapeutics [Member]
Segment reporting
Loss from operations	(1,856,553)	(2,034,507)	$ (5,396,630)	(4,867,481)
Amortization and depreciation	2,876	1,883	8,273	5,644
Other (Expense) Income, Net	(12,613)	(26,123)	110,975	99,512
Share-based compensation	28,343	28,506	85,190	86,816
Identifiable Assets	121,567		121,567		128,645
Operating Segments [Member] | Public Health Solutions [Member]
Segment reporting
Total revenues	166,140	186,198	582,843	548,615
Loss from operations	(9,578)	(160,970)	(131,201)	(399,512)
Amortization and depreciation	479	314	1,379	941
Share-based compensation	1,054	6,518	3,162	20,002
Identifiable Assets	137,910		137,910		146,296
Corporate, Non-Segment [Member]
Segment reporting
Loss from operations	(1,215,113)	(1,169,434)	(5,141,095)	(3,320,184)
Amortization and depreciation	1,438	6,678	11,886	20,029
Other (Expense) Income, Net	(215,146)	(196,517)	(641,768)	(224,174)
Share-based compensation	41,318	$ 44,697	132,304	$ 148,329
Identifiable Assets	$ 17,687,896		$ 17,687,896		$ 26,594,986